+/-9-HETE | 70968-92-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: +/-9-HETE
• 英文别名: 9-hydroxyeicosatetraenoic acid；9-hydroxy-5Z,7E,11Z,14Z-eicosatetraenoic acid；(5Z,7E,11Z,14Z)-9-hydroxyicosa-5,7,11,14-tetraenoic acid
• CAS: 70968-92-2
• 化学式: C₂₀H₃₂O₃
• 分子量: 320.472
• InChiKey: KATOYYZUTNAWSA-OIZRIKEUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  23
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  tert-Butyl-(1-{(1E,3Z)-5-[(4-methoxy-phenyl)-diphenyl-methoxy]-penta-1,3-dienyl}-dodeca-3,6-diynyloxy)-diphenyl-silane 在 Lindlar's catalyst 吡啶 、 lithium hydroxide 、 sodium chlorite 、 CBr₄(Ph₂PCH₂)2 、 四丁基氟化铵 、 氢气 、 溶剂黄146 、 N,N'-二环己基碳二亚胺 、 三氟乙酸 作用下， 以 四氢呋喃 、 吡啶 、 六甲基磷酰三胺 、 乙二醇二甲醚 、 正己烷 、 二氯甲烷 、 水 、 二甲基亚砜 、 叔丁醇 、 苯 为溶剂， 反应 16.0h， 生成 +/-9-HETE
  参考文献：
  名称：

  Synthesis of ± 8- and 9-HETEs

  摘要：

  DOI：

  10.1016/s0040-4039(01)91141-4

文献信息

• Repurposing Resveratrol and Fluconazole To Modulate Human Cytochrome P450-Mediated Arachidonic Acid Metabolism
  作者：Ahmed A. El-Sherbeni、Ayman O. S. El-Kadi

  DOI：10.1021/acs.molpharmaceut.5b00873

  日期：2016.4.4

  Cytochrome P450 (P450) enzymes metabolize arachidonic acid (AA) to several biologically active epoxyeicosatrienoic acids (EETs) and hydroxyeicosatetraenoic acids (HETEs). Repurposing clinically-approved drugs could provide safe and readily available means to control EETs and HETEs levels in humans. Our aim was to determine how to significantly and selectively modulate P450-AA metabolism in humans by

  细胞色素P450（P450）酶将花生四烯酸（AA）代谢为几种具有生物活性的环氧二十碳三烯酸（EET）和羟基二十碳四烯酸（HETE）。重新使用经过临床批准的药物可以为控制人类中的EET和HETE水平提供安全且容易获得的手段。我们的目标是确定如何通过临床批准的药物显着和选择性地调节人体内的P450-AA代谢。液相色谱-质谱法用于测定人重组P450酶以及人肝和肾微粒体形成的15种AA代谢产物。CYP2C19显示最高的EET形成活性，而CYP1B1和CYP2C8显示最高的中链HETE形成活性。CYP1A1和CYP4分别显示出最高的亚末端和20-HETE形成活性。与研究药物相比，白藜芦醇和氟康唑对肝P450-AA代谢产生了最有选择性和最显着的调节作用。蒙特卡洛模拟显示，每天服用2.5克后，有90％的人口在16-，18-和20-HETE形成中分别减少6-22％，16-39％和16-35％。白藜芦醇，氟康唑50
• Oxidation of oxa and thia fatty acids and related compounds catalysed by 5- and 15-lipoxygenase
  作者：Christopher J. Easton、Thomas A. Robertson、Michael J. Pitt、Deborah A. Rathjen、Antonio Ferrante、Alfred Poulos

  DOI：10.1016/s0968-0896(00)00246-7

  日期：2001.2

  The modified fatty acids, (Z,Z,Z)-(octadeca-6,9,12-trienyloxy)acetic acid, (Z,Z,Z)-(octadeca-9,12,15-trienyloxy)acetic acid, (all-Z)-(eicosa-5,8,11,14-tetraenyloxy)acetic acid, (all-Z)-(eicosa-5,8,11,14-tetraenylthio)acetic acid, 3-[(all-Z)-(eicosa-5,8,11,14-tetraenylthio)]propionic acid, (all-Z)-(eicosa-5,8,11,14-tetraenylthio)succinic acid, N-[(all-Z)-(eicosa-5,8,11,14-tetraenoyl)]glycine and N-[(all-Z)-(eicosa-5,8,11,14-tetraenoyl)]aspartic acid, all react with soybean 15-lipoxygenase. The products were treated with triphenylphosphine to give alcohols, which were isolated using HPLC. Analysis of the alcohols using negative ion tandem electrospray mass spectrometry, and by comparison with compounds obtained by autoxidation of arachidonic acid, shows that each enzyme catalysed oxidation occurs at the omega -6 position of the substrate. In a similar fashion, it has been found that (Z,Z,Z)-(octadeca-6,9,12-trienyloxy)acetic acid, (Z,Z,Z)-(octadeca-9,12,15-trienyloxy)acetic acid, (all-Z)-(eicosa-5,8,11,14-tetraenylthio)acetic acid and N-[(all-Z)-(eicosa-5,8, 11.14-tetraenylthio)]propionic acid each undergoes regioselective oxidation at the carboxyl end of the polyene moiety on treatment with potato 5-lipoxygenase. Neither (all-Z)-(eicosa-5,8,11,14-tetraenylthio)succinic acid nor N-[(all-Z)-(eicosa-5,8,11,14-tetraenoyl)]aspartic acid reacts in the presence of this enzyme, while N-[(all-Z)-(eicosa-5,8,11,14-tetraenoyl)]glycine affords the C11' oxidation product. The alcohol derived from (Z,Z,Z)-(octadeca-6,9, 12-trienyloxy)acetic acid using the 15-lipoxygenase reacts at the C6' position with the 5-lipoxygenase. (C) 2001 Elsevier Science Ltd. All rights reserved.
• KUHN, HARTMUT;WIESNER, RAINER, J. CHROMATOGR. , 520,(1990) C. 391-401
  作者：KUHN, HARTMUT、WIESNER, RAINER

  DOI：——

  日期：——
• MODIFIED POLYUNSATURATED FATTY ACIDS
  申请人：Peptech Limited

  公开号：EP0869941B1

  公开（公告）日：2001-12-12
• TREATMENT OF A DISEASE MEDIATED BY ARACHIDONIC ACID OR AN EICOSANOID
  申请人：GADAMIAN Robert

  公开号：US20190231730A1

  公开（公告）日：2019-08-01

  Disclosed is a method of treating a disease mediated by arachidonic acid or an eicosanoid. The method includes administering to a subject in need thereof an effective amount of an analogue of arachidonic acid or an analogue of eicosanoid. The analogue is a dehydro-analogue of an arachidonic acid, HPETE, EET, a prostaglandin or HETE. Diseases that may be treated include cancer, ischemic heart disease, psoriasis, cystic fibrosis, Alzheimer's disease, allergy, COPD, rheumatoid arthritis (RA), ulcerative colitis, or Crohn's disease.